Form 6-K ASTRAZENECA PLC For: Jun 09
Tweet
Share
E-mail
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of June 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
09 June 2023
AstraZeneca announces agreement with Quell
Therapeutics
to develop, manufacture and commercialise
engineered T-regulatory cell therapies for autoimmune
diseases
Collaboration focused on Type 1 Diabetes and Inflammatory Bowel
Disease
using Quell's proprietary multi-modular T-regulatory cell
engineering
AstraZeneca has entered into an exciting collaboration, exclusive
option and license agreement with Quell Therapeutics to develop
multiple engineered T-regulator (Treg) cell therapies that have the
potential to be curative in Type 1 Diabetes (T1D) and Inflammatory
Bowel Disease (IBD) indications.
Under the terms of the agreement, Quell's proprietary toolbox of
Treg cell engineering modules, including its innovative Foxp3
Phenotype Lock will be leveraged to develop autologous
multi-modular Treg cell therapy candidates for major autoimmune
disease indications.
Iain McGill, Chief Executive Officer of Quell Therapeutics, said:
"We are extremely pleased to have AstraZeneca on board as our first
major partner. This collaboration builds on our pioneering work to
develop exquisitely engineered, multi-modular Treg cell therapies
for immune disorders and provides excellent validation for the
technologies and capabilities we have established. We are proud and
incredibly excited to partner our leading science with the deep
experience of AstraZeneca to accelerate the application of our Treg
cell therapy platform in major autoimmune disease, where we believe
there is a broad opportunity to reset immune tolerance and drive
durable responses for patients."
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D
at AstraZeneca, said: "This is a very exciting collaboration with
Quell as we look to expand our next-generation therapeutic toolbox
and explore the untapped potential with Treg cell therapies in
autoimmune indications. This is aligned with our strategy to target
underlying disease drivers to stop or slow disease progression and
ultimately accelerate the delivery of transformative care to
patients with chronic autoimmune conditions."
AstraZeneca will have the option to further development and
commercialisation of successful clinical candidates in T1D and
IBD.
Financial considerations
Quell will receive $85 million upfront from AstraZeneca, which
comprises a predominant cash payment and an equity investment.
Quell is also eligible to receive over $2 billion for further
development and commercialisation milestones, if successful, plus
tiered royalties.
In addition, Quell retains an option, which can be exercised either
after approval of an Investigational New Drug (IND) application or
at the end of the Phase I/II clinical study, to co-develop Treg
cell therapies from the T1D programme with AstraZeneca in the
United States in exchange for additional milestone payments and
increased royalties on US net sales.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
AstraZeneca PLC
INDEX
TO EXHIBITS
AstraZeneca agreement with Quell Therapeutics
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
09 June 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
- Farmers & Merchants Bank of Long Beach Reports 2024 First Quarter Results
- Enhanced Inventory Management Solutions to Meet Rising E-Commerce Demand
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
